Table. Characteristics of participants in study of MDR TB, Harare, Zimbabwe, 2011–2012*.
| Characteristic |
MDR-TB, n = 25 |
Monoresistant TB, n = 14 |
Drug-sensitive TB, n = 90 |
Unconfirmed TB, n = 84 |
p value |
|---|---|---|---|---|---|
| Age, median (IQR) | 34 (27–42) | 35 (29–45) | 37 (30–44) | 39 (32–48) | 0.67 |
| Male, no. (%) |
13 (52) |
6 (43) |
58 (64) |
48 (57) |
0.36 |
| Retreatment category, no. (%) | |||||
| Treatment failure | 9 (36) | 0 | 9 (10) | 21 (25) | <0.001 |
| Late smear conversion | 8 (32) | 1 (7) | 30 (33) | 13 (16) | |
| Default | 0 (0.0) | 2 (14) | 13 (14) | 7 (8) | |
| Relapse | 7 (28) | 7 (50) | 34 (38) | 34 (41) | |
| New |
1 (4) |
4 (29) |
1 (1) |
4 (5) |
|
| Sputum smear positivity, no. (%) |
20 (80) |
7 (50) |
52 (53) |
6 (7) |
<0.001 |
| HIV infection, no. (%) | 18 (72) | 13 (93) | 57 (65) | 69 (82) | 0.02 |
| Antiretroviral treatment, no. (%) |
14 (78) |
10 (77) |
41 (72) |
52 (75) |
0.95 |
| Time receiving TB treatment, median (IQR) |
98 (4–175) |
0 (0–3) |
31 (2–103) |
101 (5–186) |
0.03 |
| Prior treatment courses, no. (%) | |||||
| None | 8 (32) | 5 (36) | 30 (33) | 21 (25) | 0.52 |
| 1 | 12 (48) | 7 (50) | 40 (44) | 40 (48) | |
| ≥2 | 5 (20) | 2 (14) | 20 (22) | 22 (27) |
*Retreatment classification was defined according to international standards (8); late smear conversion was defined as sputum AFB smear-positivity after month 3 but before month 5 of treatment. Monoresistant TB was defined as resistance to either isoniazid or rifampin, but not both. The denominator for antiretroviral treatment included persons with HIV infection. MDR TB, multidrug-resistant tuberculosis; IQR, interquartile range; AFB, acid-fast bacilli.